I agree that this site is using cookies. You can find further informations here.
X
Freidlin, Boris
126  results:
Search for persons X
?
1

Design of randomized clinical trials with a binary endpoint..:

Korn, Edward L. ; Freidlin, Boris
Statistics in Medicine.  43 (2024)  16 - p. 3109-3123 , 2024
Link: https://doi.org/10.1002/..
 
?
2

Statistical Considerations in Pediatric Cancer Trials: Repo..:

Sridhara, Rajeshwari ; Marchenko, Olga ; Jiang, Qi...
Statistics in Biopharmaceutical Research.  15 (2023)  4 - p. 845-851 , 2023
Link: https://doi.org/10.1080/..
 
?
3

The potential to backfill in phase I trials: the National C..:

Foster, Jared C ; Korn, Edward L ; Freidlin, Boris.
JNCI Cancer Spectrum.  7 (2023)  6 - p. , 2023
Link: https://doi.org/10.1093/..
 
?
4

National Cancer Institute Combination Therapy Platform Tria..:

Meric-Bernstam, Funda ; Ford, James M. ; O'Dwyer, Peter J....
Clinical Cancer Research.  29 (2023)  8 - p. 1412-1422 , 2023
Link: https://doi.org/10.1158/..
 
?
5

Dose optimization during drug development: whether and when..:

Korn, Edward L ; Moscow, Jeffrey A ; Freidlin, Boris
JNCI: Journal of the National Cancer Institute.  115 (2022)  5 - p. 492-497 , 2022
Link: https://doi.org/10.1093/..
 
?
6

Cancer Clinical Trials beyond Pandemic: Report of an Americ..:

Sridhara, Rajeshwari ; Barksdale, Elizabeth ; Marchenko, Olga...
Statistics in Biopharmaceutical Research.  15 (2022)  2 - p. 444-449 , 2022
Link: https://doi.org/10.1080/..
 
?
7

Clinical Benefit Scales and Trial Design: Some Statistical ..:

Korn, Edward L ; Allegra, Carmen J ; Freidlin, Boris
JNCI: Journal of the National Cancer Institute.  114 (2022)  9 - p. 1222-1227 , 2022
Link: https://doi.org/10.1093/..
 
?
8

Improving precision oncology through better designs and rep..:

LoRusso, Patricia M ; Freidlin, Boris
JNCI: Journal of the National Cancer Institute.  115 (2022)  2 - p. 122-124 , 2022
Link: https://doi.org/10.1093/..
 
?
9

Augmenting randomized clinical trial data with historical c..:

Freidlin, Boris ; Korn, Edward L
JNCI: Journal of the National Cancer Institute.  115 (2022)  1 - p. 14-20 , 2022
Link: https://doi.org/10.1093/..
 
?
10

Time trends with response-adaptive randomization: The inevi..:

Korn, Edward L ; Freidlin, Boris
Clinical Trials.  , 2022
Link: https://doi.org/10.1177/..
 
?
11

Gaps and opportunities in the treatment of relapsed-refract..:

Kumar, Shaji ; Baizer, Lawrence ; Callander, Natalie S....
Blood Cancer Journal.  12 (2022)  6 - p. , 2022
Link: https://doi.org/10.1038/..
 
?
12

A Problematic Biomarker Trial Design:

Freidlin, Boris ; Korn, Edward L
JNCI: Journal of the National Cancer Institute.  114 (2021)  2 - p. 187-190 , 2021
Link: https://doi.org/10.1093/..
 
?
13

Are restricted mean survival time methods especially useful..:

Freidlin, Boris ; Hu, Chen ; Korn, Edward L
Clinical Trials.  18 (2021)  2 - p. 188-196 , 2021
Link: https://doi.org/10.1177/..
 
?
14

Reply to Quartagno et al:

Freidlin, Boris ; Hu, Chen ; Korn, Edward L
Clinical Trials.  18 (2021)  6 - p. 746-746 , 2021
Link: https://doi.org/10.1177/..
 
?
15

Evaluation of the contribution of randomised cancer clinica..:

Foster, Jared ; Freidlin, Boris ; Korn, E.L..
ESMO Open.  5 (2020)  5 - p. e000871 , 2020
Link: https://doi.org/10.1136/..
 
1-15